Trials / Completed
CompletedNCT04054986
Study of the Imaging Agent 18F-Var3 in Patients With Breast Cancer
Phase 1 Study Using First-in-Human Acidosis Imaging With [18F]AlF-cysVar3 pHLIP® (18F-Var3) in Patients With Breast Cancer for Determination of Safety, Biodistribution and Radiation Dosimetry
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to measure the safety of the investigational imaging agent, 18F-Var3 and to determine if it is helpful in providing information about how tumor tissues behave.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | F-Var3 PET/CT | Participants will undergo up to 5 serial F-Var3 PET/CT scans within 25 minutes of the injection of 18F-Var3, 30, 60, 120 and 240 minutes after injection of the 18FVar3. |
| OTHER | Blood draw | Collection of blood for research tests before the injection, 30, 60, 120 and 240 min after the injection. |
Timeline
- Start date
- 2019-08-09
- Primary completion
- 2020-09-18
- Completion
- 2020-09-18
- First posted
- 2019-08-13
- Last updated
- 2025-05-16
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04054986. Inclusion in this directory is not an endorsement.